Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

sed sodium excretion versus baseline (28%, 138%, 55% and 158% average change, respectively) and increased plasma cGMP versus baseline (4%, 202%, 378% and 691% average change, respectively).

With respect to safety assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) had no effect on mean arterial pressure versus baseline (-5%, 6%, -6%, -8% average change, respectively), had no effect on serum potassium levels versus baseline (0%, -2%, 3%, 3% average change, respectively), and had no effect on renal function as measured by GFR versus baseline (1%, 8%, 3%, 4% average change, respectively).

The four-hour infusion of CD-NP was well tolerated in all subjects at all dose levels tested. At the highest dose (25 ng/kg/min) of CD-NP, after completing the four-hour infusion, in response to an orthostatic challenge, some subjects exhibited transient symptoms consistent with volume depletion and/or vasodilatation including dizziness, asymptomatic tachycardia and orthostatic hypotension. These events are indicative of a practical limit of pharmacologic activity in normal healthy subjects, and Nile intends to investigate higher doses in upcoming Phase 1b studies of CD-NP infusions in heart failure patients.

"In this trial in healthy subjects, we demonstrated that CD-NP can be safely administered and elicits pharmacological and clinical effects which are consistent with the proposed mechanism of action. We are planning additional phase 1 trials in heart failure patients with the goals of determining the therapeutic dose range for diuresis, natriuresis, and cardiac filling pressure reducing effects, while maintaining systemic blood pressure and preserving renal function," commented Peter Strumph, Chief Executive Officer of Nile.

About CD-NP

CD-NP is a rationally-designed synthetic peptide designed to incorporate the optimal components of naturally occurring natriuretic peptides, creating a novel compound with unique actions in vivo. CD-NP is a selecti
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Larry J. Merlo , President and CEO of CVS ... National Press Club in Washington, D.C. ... selling tobacco products and its leadership in driving the innovations ... changes in our health care system pose enormous challenges to ... "CVS Health has a truly unique combination of business assets ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... PLEASANTON, Calif., Dec. 2 Roche (SIX: RO, ROG; OTCQX: ... Administration (FDA) approved an additional intended use for its licensed ... of up to 96 individual donations. The test, called the ... s 201 system, is a qualitative, in-vitro test for ...
... , NANJING, China, Dec. 2 ... SCR ), a leading pharmaceutical company,specializing in ... pharmaceuticals in China, today reported that its,subsidiary Jiangsu Yanshen ... of all its products in order to conduct an,internal ...
Cached Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
(Date:9/20/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and retailer, ... . In addition, the company has launched a special offer ... is to benefit all of its big fans. Worldwide people ... , Along with beautiful party dresses, the company also ... released its new sexy short prom outfits and purple homecoming ...
(Date:9/20/2014)... Weight Destroyer , a weight loss ... Wren that has already helped tens of thousands of ... like high blood pressure, high cholesterol, and accelerated aging ... investigative review. , “Weight Destroyer is totally turning ... showing people what is truly effective when it comes ...
(Date:9/20/2014)... September 20, 2014 The Villa Group ... del Palmar Cabo San Lucas, Villa La Estancia and ... Hurricane Odile, with plans to welcome guests back to ... of Sept. 19, all members and guests of the ... to a coordinated effort with government authorities. , ...
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Ticket ... Grande concert tickets . This popular ticket exchange is ... , The 2015 schedule of tours is beginning ... have already announced their plans to hit the road, including ... Raton, Fla., announced the “Honeymoon Tour,” which will take her ...
Breaking Medicine News(10 mins):Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3
... , ... and his foundation to raise money to help the people of Haiti. It is Mr. Kent and ... ... Capital, LLC., and CEO of the Kent Marketing Group to join forces with former NFL player Jack ...
... ... April 1 – May 30, people age 65 and older can call to determine if they ... ... of change, but don’t worry if you don’t have the change to spare for an eye ...
... The American Academy ... wrinkles that become etched into the surface of the skin and don,t disappear once you,re ... the face and the pillow, allowing the delicate facial skin, to remain smooth for the ... ...
... ... MDX/American Registry Medical Patient,s Choice Award. , ... (Vocus) March 30, 2010 -- Five Summit Medical Group physicians ... Gruber, M.D., Jed A. Kwartler, M.D., Eric Mrisky, M.D., and Monib Zirvi, M.D., join ...
... ... Processes, an internationally recognized leader in literacy research, remediation, and professional development, will ... campaign beginning April 1st, 2010. , ... San Luis Obispo, CA (Vocus) -- Lindamood-Bell ...
... Global Initiative (BHGI) and the Latin American & Caribbean ... biennial BHGI Global Summit on International Breast Health June ... international organizations to address the optimization of breast health ... 2010 Summit is "Optimizing Health Care Delivery." ...
Cached Medicine News:Health News:Thomas J. Kent Jr. FDP Capital, LLC Chairman and Former NFL Player Jack Brewer Join Forces 2Health News:EyeCare America Ushers in the New Season and Springs for Eye Exams for Qualified Seniors 2Health News:EyeCare America Ushers in the New Season and Springs for Eye Exams for Qualified Seniors 3Health News:Mumbani™ Fresh Face Pillow, an Anti-Aging and Anti-Wrinkle Sleep Accessory for Side and Stomach Sleepers! 2Health News:Mumbani™ Fresh Face Pillow, an Anti-Aging and Anti-Wrinkle Sleep Accessory for Side and Stomach Sleepers! 3Health News:Summit Medical Group Physicians Receive Patients' Choice Award 2Health News:Summit Medical Group Physicians Receive Patients' Choice Award 3Health News:Lindamood-Bell to Help Commemorate Autism Awareness Day 2Health News:Lindamood-Bell to Help Commemorate Autism Awareness Day 3Health News:Lindamood-Bell to Help Commemorate Autism Awareness Day 4Health News:The Global Summit on International Breast Health 2
Standard vice clamp, can be fitted instead of Quick Realease Cassette...
... freezing stage is a refrigerated design for use ... for use with the 8000 sledge microtome, however, ... ,The refrigerated stage gives a large working area ... ridged to provide good adhesion between the specimen ...
... work, it is necessary to cool a specimen ... be fitted to most microtomes and will permit ... depending on conditions. The equipment consists of a ... stage is best suited for operation with a ...
... MNL 4404 & 4405 series Freezing Stages ... devices have no moving parts and need only ... water for operation. Freezing starts immediately ... is adjustable so that optimum cutting temperatures can ...
Medicine Products: